Outcome of BCG Vaccination in ADA-SCID Patients: A 12-Patient Series.
Daniele CanaruttoChiara OltoliniFederica BarzaghiValeria CalbiMaddalena MigliavaccaFrancesca TucciVera GalloGiulia ConsiglieriFrancesca FerruaSalvatore RecuperoMaria Celia CerviHamoud Al-MousaAnna Pituch-NoworolskaChiara Tassan DinPaolo ScarpelliniPaolo SilvaniClaudia FossatiMiriam CasiraghiDaniela Maria CirilloAntonella CastagnaMaria Ester BernardoAlessandro AiutiMaria Pia CicalesePublished in: Biomedicines (2023)
Vaccination with Bacillus Calmette-Guérin (BCG) can be harmful to patients with combined primary immunodeficiencies. We report the outcome of BCG vaccination in a series of twelve patients affected by adenosine deaminase deficiency (ADA-SCID). BCG vaccination resulted in a very high incidence of complications due to uncontrolled replication of the mycobacterium. All patients who developed BCG-related disease were treated successfully and remained free from recurrence of disease. We recommend the prompt initiation of enzyme replacement therapy and secondary prophylaxis to reduce the risk of BCG-related complications in ADA-SCID patients.